AlphaVax.

PositionTriangle - Brief Article

RESEARCH TRIANGLE PARK -- Vaccine maker AlphaVax received two biodefense grants totaling $16.6 million over the next four years from the National Institutes of Health. It will get $9.1 million to develop a vaccine for botulinum neurotoxins, which block nerve functions and can cause...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT